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Renal dysfunction in allogeneic hematopoietic cell transplan- the late 1960s [1]. As the current indications for alloge-
tation. neic HCT expand, the number of patients undergoing
Background. Allogeneic hematopoietic cell transplantation this intensive treatment will continue to increase. Unfor-(HCT), formerly called bone marrow transplantation, can po-
tunately, patients undergoing HCT still face multiple tox-tentially cure various malignant and non-malignant diseases,
icities, and a substantial mortality rate [2]. Acute renalbut it is associated with a high risk of toxicity. We have pre-
viously shown an overall 21% incidence of severe acute renal failure is undoubtedly one of the major organ toxicities
failure in patients undergoing autologous HCT. The present associated with this procedure. Zager demonstrated that
study evaluated renal dysfunction in patients undergoing allo- 53% of patients undergoing HCT had doubling of thegeneic HCT.
serum creatinine with almost half of those patients re-Methods. The clinical course of 88 adult patients who re-
quiring dialysis [3]. The overall mortality of acute renalceived allogeneic HCT at the University of Colorado Health
Science Center was analyzed. Renal dysfunction was classified failure requiring dialysis with HCT has been reported to
as follows: Grade 0 normal renal function; Grade 125% range between 84 and 88% [2, 4]. While many potential
decrement in GFR but twofold rise in serum creatinine; etiologies (sepsis, hypotension, nephrotoxic antibiotics,Grade 2  twofold increase in serum creatinine; Grade 3 
chemoradiotherapy) may contribute to the occurrence oftwofold increase in serum creatinine and need for dialysis.
renal dysfunction in autologous HCT, allogeneic HCT hasResults. Of the 88 patients, 81 (92%) patients had some de-
gree of renal dysfunction (Grade 1, 20 patients; Grade 2, 32 the additional risk of graft-versus-host disease (GVHD)
patients; Grade 3, 29 patients). Severe nephrotoxicity (Grade 2 and cyclosporine A (CsA) immunosuppression therapy.
and Grade 3 renal dysfunction) was associated with signifi-
A retrospective analysis of 232 patients undergoing au-cantly higher frequencies of sepsis, hepatic toxicity and hepatic
tologous HCT at our institution, the University of Colo-veno-occlusive disease (VOD), and lung toxicity. The overall
mortality rate at the end of 6 months was 58%. Grade 3 renal rado Health Sciences Center (UCHSC), had reported a
dysfunction was associated with a significantly increased risk 21% incidence of acute renal failure [5]. In hopes of
of mortality (82.6%). better understanding the differences between the autolo-
Conclusion. A 92% incidence of renal dysfunction in alloge-
gous and allogeneic HCT with regards to renal dysfunc-neic HCT patients was found. Lung and liver toxicities were
tion, we evaluated 88 patients who underwent allogeneicsignificantly correlated with developing renal dysfunction, and
the mortality rates for patients with Grade 3 renal failure ex- HCT at UCHSC.
ceeded 80%.
METHODS
Allogeneic hematopoietic cell transplantation (HCT) Patients
has gained worldwide acceptance as a treatment for vari- The clinical course of 91 consecutive patients who
ous diseases, since it was first successfully performed in underwent an allogeneic HCT at our institution between
January 1995 and September 2000 were analyzed. Three
patients were excluded because two of them were receiv-Key words: bone marrow transplantation, allogeneic, nephrotoxicity,
acute renal failure, organ toxicity. ing a second allogeneic HCT and the remaining one died
on the third day after HCT due to an unrelated cause.Received for publication January 10, 2002
Patients who received non-myeloablative HCT (“mini-and in revised form February 25, 2002
Accepted for publication March 11, 2002 allo” transplant) were not included in this study. A re-
view of computerized medical records of these 88 pa- 2002 by the International Society of Nephrology
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tients for information on age, gender, type and duration concentration and a creatinine clearance calculated by
the MDRD equation [GFR (mL/min/1.73 m2)  186 *of disease, chemotherapy and conditioning regimen and
renal, hepatic and pulmonary functions before and after PCr1.154 * age0.0203 * 1.212 if black * 0.742 if female) [6].
These parameters were measured on days 7, 1, 7,the transplant was undertaken.
All 88 patients underwent an initial evaluation prior 14, 21, 28, 60, 90, 180 days, and at the end of the first
year. Renal dysfunction was classified according to theto treatment that included history and physical examina-
tion, baseline laboratory testing, chest x-ray, pulmonary serum creatinine concentration and creatinine clearance.
Grade 0, that is, normal renal function was equivalentfunction tests, cardiac nucleotide-gated blood pool scan-
ning (MUGA), electrocardiogram and creatinine clear- to a decrease in creatinine clearance of less than 25%
of the baseline value. Grade 1 renal dysfunction corre-ance calculated using the MDRD formula. Patients were
accepted for transplantation only if they had adequate sponded to a less than twofold rise in serum creatinine
concentration with a decrease in creatinine clearancerenal, liver, pulmonary and cardiac function as previ-
ously described [5]. Only one patient had a significantly greater than 25% of the baseline value. Grade 2 renal
dysfunction corresponded to greater than twofold risedecreased creatinine clearance (60 mL/min) before re-
ceiving the allogeneic HCT. in serum creatinine concentration of the baseline value
but not requiring dialysis. Grade 3 renal dysfunctionAll patients signed informed consent documents prior
to treatment and were treated on protocols approved by corresponded to patients with Grade 2 parameters but
requiring dialysis. Veno-occlusive disease (VOD) of thethe UCHSC Review Board.
liver was defined as the occurrence of at least two of the
High-dose conditioning regimen following criteria within 20 days of transplantation: (1)
Hyperbilirubinemia (total serum bilirubin concentrationAll patients were hospitalized for treatment. The che-
motherapy protocols used are shown in Table 1. None 2 mg/dL), (2) hepatomegaly or right upper quadrant
pain, and (3) sudden unexplained weight gain (2% ofof the patients received reduced intensity conditioning
regimens (“mini-allo” transplant). Bone marrow and pe- baseline body weight) [7]. Transaminasemia was defined
as increase in aspartate aminotransferase (AST) or ala-ripheral stem cells from related (50%) and unrelated
(17%) donors were used as source of hematopoietic pro- nine aminotransferase (ALT) by greater than two times
the normal laboratory values.genitors. Cryopreserved umbilical cord blood was used
as a source of hematopoietic progenitor cells in the re-
Statistical methodsmaining 33% cases.
Broad spectrum antibacterial prophylaxis was used for Continuous variables are reported as mean SD. For
dichotomous variables the frequency of positive occur-neutropenia and empiric treatment of fever. Antibiotics
usually included gentamicin (2.5 mg/kg initial dose then rences are given along with their corresponding percent-
ages. Various baseline factors and subsequent clinical1.5 mg/kg every 8 hours), piperacillin (3 g every 4 hours)
or a third generation cephalosporin and vancomycin (1 g values were compared between the four groups of renal
failure as described above. Comparisons of continuousevery 12 hours). If the fever persisted for more than
48 hours, then amphotericin B therapy was added to variables between various groups of renal dysfunction
were facilitated by using either the unpaired Studentantibiotics as a daily four-hour infusion at a conventional
dose of 0.6 mg/kg. Some patients received newer, less t test, or an analysis of variance (ANOVA). Associations
between the latter groupings and dichotomous varia-toxic forms of amphotericin B. Patients received GVHD
prophylaxis with CsA and methotrexate or CsA and bles were examined using the chi-square test, or Fisher’s
exact test where appropriate. The relative contributionsprednisone. Beginning one day before HCT (day 1)
CsA was administered by continuous daily infusion or of continuous and dichotomous variables on the outcome
of grade of renal dysfunction were examined using step-by twice daily infusions until oral CsA could be tolerated.
The starting dose was 4 mg/kg/day, adjusted for eleva- wise multiple logistic regression. SAS statistical software
(version 8.2; SAS Institute, Cary, NC, USA) was usedtions in bilirubin or serum creatinine concentration to
maintain whole blood levels of 350 to 450 ng/mL. Metho- for all analysis.
trexate was infused intravenously at a dose of 15 mg/m2
on day 1 and 10 mg/m2 on days 3 and 6.
RESULTS
Patient baseline characteristicsPatient monitoring
Patients were monitored during their entire hospital The baseline characteristics of the 88 patients included
in the study are shown in Table 1. There was a predomi-course for complications including sepsis (documented
by positive blood cultures), hypotension (defined as sys- nance of females as compared to males but their ages
were similar. Although the plasma creatinine concentra-tolic blood pressure 90 mm Hg), and organ toxicities.
Renal function was assessed by the serum creatinine tions and creatinine clearances were within the normal
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Table 1. Baseline characteristics of patients who received an allogenic The platelet count decreased from a mean baseline
hematopoietic cell transplantation (HCT)
value of 174,670  21,760/mm3 on day 7 to 43,247 
Characteristic Whole group Males Females P value 8407/mm3 on day7 (P 0.001 vs. day7) and 43,054
Number 88 35 53 7335/mm3 on day 14 (P  0.001 vs. day 7), remained
Age years 38.79.7 37.211.8 39.78.5 NS low until day 60 post-transplantation with a value of
Serum creatinine mg/dL 0.780.25 0.910.31 0.700.14 0.05
83,241  10,098/mm3 (P  0.001).Creatinine clearance
mL/min/1.73 m2 10629.5 11134.5 10225.5 0.05 Hemoglobin and hematocrit values fell from baseline
values of 11.38  0.21 g/dL and 33.49  0.64%, respec-
Characteristic Number of patients
tively, to 10.40  0.12 g/dL for hemoglobin (P  0.01)
Race and 30.36  0.3 for hematocrit (P  0.001) on day 7.
White 70 Hemoglobin values were not significantly different fromHispanic 16
baseline on day 60 with a value of 10.67  0.21 g/dLAfrican American 1
Oriental 1 (P  0.05).
Diagnosis During chemotherapy there was a statistically signifi-Chronic myelogenous leukemia (CML) 22
cant decrease from the baseline values for serum albu-Acute myelogenous leukemia (AML) 24
Non Hodgkin’s lymphoma (NHL) 15 min, total protein, sodium, calcium, uric acid, cholesterol,
Acute lymphocytic leukemia (ALL) 10 carbon dioxide; no difference in chloride, magnesium, po-Breast cancer 7
tassium, lactic dehydrogenase; and an increase in plasmaHodgkin’s disease 4
Chronic lymphocytic leukemia (CLL) 3 glucose, blood urea nitrogen, alkaline phosphatase, and
Chronic myelomonocytic leukemia (CMML) 1 phosphorus values compared to baseline (data not shown).Myelodysplastic syndrome 1
Multiple myeloma 1
Changes in renal functionConditioning regimens
Cyclophosphamide  busulfan 28 An analysis of the 88 transplantation procedures re-Busulfan  melphalan 24
vealed a significant rise in serum creatinine from theCyclophosphamide  TBI 3
Melphalan  TBI 33 baseline value of 0.78 0.25 mg/dL, to a value of 1.62
Abbreviations are: NS, non-significant; TBI, total body irradiation. 0.83 mg/dL on day 14 (P  0.01). Serum creatinine
concentration was 1.54  1.32 mg/dL at day 90, and
1.92  1.75 mg/dL at the end of 6 months (P  0.0001
versus day 7). However, it should be recognized thatrange in both genders, both were significantly lower in fe-
the serum creatinine values given above are means ofmales as compared to males. The diagnosis and high
the values among the patients surviving at that point ofdose conditioning regimens for each patient are shown
time. The graphic representation of the trend in serumin Table 1. Different treatment protocols were used ac-
creatinine and GFR is given in Figure 1 and Figure 2,cording to the diagnosis and the stage of the underlying
respectively.diseases.
The changes in renal function were then analyzedA total of 36 (41%) patients received total body irradi-
based on the severity of renal dysfunction (Grades 0 toation (TBI) in addition to chemotherapy. Thirty-one
3). Eighty-one out of 88 patients (92%) had Grades 1(35.2%) patients were treated with chemotherapy regi-
to 3 renal dysfunction within the first month of the alloge-mens that included cyclophosphamide as one of the
neic HCT. Twenty (22.7%) patients had Grade 1, 32drugs. There were no statistically significant differences
patients (36.36%) had Grade 2, and 29 patients (32.9%)between the groups of patients who were treated or not
had Grade 3 renal dysfunction. Only 7 patients (7.9%)treated with TBI in terms of age, gender, and baseline
had normal creatinine clearance at the end of one monthrenal function (Table 2). There was also no statistically
(Table 3). The mean baseline (day –7) serum creatininesignificant difference in terms of age, gender, and base-
concentration was 0.78  0.25 mg/dL and did not differline creatinine clearance values in the patient groups who
significantly among the three groups (Grade 0, 0.94 did and did not receive cyclophosphamide (Table 2).
0.2 mg/dL; Grade 1, 0.79  0.2 mg/dL; Grade 2, 0.75 
Treatment related changes in laboratory values 0.16 mg/dL; Grade 3, 0.80 0.3 mg/dL). For the patients
with Grade 2 or 3 renal dysfunction, the average numberAfter conditioning therapy, a profound pancytopenia
of days post-transplant for the doubling of serum creati-occurred in all patients, and the mean white blood cell
nine concentration was 16.2  6.1 days. Five of the pa-count fell from 11,069 1915/mm3 before chemotherapy
tients with Grade 3 renal dysfunction showed a doubling(day 7) to 1929  1376/mm3 on day 7 post-trans-
of serum creatinine concentration within the first weekplantation (P  0.001). Evidence of hematopoietic re-
post-HCT, while 20 patients with Grade 3 renal dysfunc-covery occurred after day 14 with a mean of 4596 
tion showed a doubling of serum creatinine in the second1377/mm3 on day14 (P 0.05 vs. day7), and 9481
1420/mm3 on day 21 (P  0.05 vs. day 7). week after transplant. Patients with Grade 1 renal dys-
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Table 2. Characteristics of patients treated with TBI and cyclophosphamide
TBI group Non-TBI group P Cyclophosphamide Non-cyclophosphamide P
Number of patients 36 52 31 57
Gender male/female 12/24 23/30 NS 12/19 23/35 NS
Age years 37.810.38 39.49.18 NS 38.49.12 38.910.01 NS
Baseline creatinine clearance
mL/min/1.73 m2 110.6825.1 10332 NS 10029.2 10929.4 NS
Fig. 1. Trend of serum creatinine after allo-
geneic hematopoietic cell transplantation
(HCT). Solid bars represent serum creatinine
values (mean  SEM).
Fig. 2. Trend of creatinine clearance after al-
logeneic hematopoietic cell transplantation.
Solid bars represent serum creatinine values
(mean  SEM). The creatinine clearance is
calculated using the MDRD equation.
function showed a similar time course with only 4 pa- time of the transplantation (Table 3). The gender distri-
bution also was not significantly different between thetients showing a 25% decline in creatinine clearance
during the first week, and 8 patients at the end of the four groups. As well, there were no significant baseline
laboratory differences between the four different renalthird week after HCT. The differences in time courses
were not statistically significant between the groups of dysfunction groups.
Of the 8 different diseases represented by these 88renal dysfunction.
The mean age of all patients at the time of transplan- patients, no one disease was associated with an increased
risk of renal dysfunction but the statistical power was in-tation was 38.7  9.7 years. There was no significant
difference between the ages of the four groups at the adequate in most instances to allow comparison (Table 4).
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Table 3. Characteristics of patients with different grades of renal dysfunction
Grade 0 Grade 1 Grade 2 Grade 3 P
Number of patients 7 20 32 29
Gender M/F 4/3 9/11 10/22 12/17 NS
Age years 35.810.4 39.610.3 398.6 38.110.1 NS
Baseline serum creatinine mg/dL 0.940.2 0.790.28 0.750.17 0.800.35 NS
Creatinine clearance mL/min/1.73 m2 9018.6 10530.2 10723.8 109.536 NS
Mortality % 3 (42.8%) 8 (40%) 16 (50%) 24 (82.7%) 0.01
Table 6. Lung and liver toxicities accompanying different gradesTable 4. Diagnosis of patients with different grades
of renal dysfunction of renal dysfunction
Number of patientsGrade Grade Grade Grade Severe
Diagnosis 0 1 2 3 nephrotoxicitya %
Grade 0 Grade 1 Grade 2 Grade 3
AML 3 5 10 5 65.2
Normal liver function 1 2 2 1NHL 0 5 5 5 66.7
Transaminitis 4 14 18 17Breast cancer 1 1 2 3 71.4
Bilirubin ↑ 5 15 29 26Hodgkin 0 1 2 1 75
Transaminitis  bilirubin ↑ 3 11 17 15Multiple myeloma 0 1 1 0 50
VODa 0 2 3 9CML 3 6 6 7 59
Lung toxicity 0 0 10 13ALL 0 0 3 7 100
Ventilatory support 3 3 10 24CMML 0 0 1 0 100
↑, increase by twofold.a Severe nephrotoxicity is defined as patients who at least doubled their serum a Hepatic venoocclusive diseasecreatinine level as compared to baseline; this includes patients with Grade 2 and
Grade 3 renal dysfunction
days in Groups 0 to 2. The variance for days of follow-
Table 5. Nephrotoxicity rates of different chemotherapeutic regimens up before death was unequal between the four groups
of renal dysfunction. Thus, the analysis of variance wasGrade Grade Grade Grade Severea
0 1 2 3 nephrotoxicity % not done to compare the time to death as it violated the
fundamental assumption of the test. However, it is clearBusulphan/
cyclophosphamide 3 7 13 5 64.2 that patients with Grade 3 renal dysfunction died earlier
Busulphan/melphalan 2 7 3 12 62.5 compared to the other groups. There were no statisticallyTBI/cyclophosphamide 0 0 2 1 100
significant difference between the mortality rates of pa-Melphalan-TBI 2 6 14 11 75.7
tients with Grade 0, Grade 1 and Grade 2 renal dysfunc-a Grade 2 and Grade 3
tion groups.
The associated complications of Grade 2 and Grade 3
renal dysfunction were significantly higher frequencies
With regards to the type of conditioning therapy, treat- of sepsis, hepatic toxicity and hepatic VOD, and lung
ment with regimens including cyclophosphamide was not toxicity (P  0.001; Table 6). Of the 29 patients with
associated with a significant increased risk of developing Grade 3 renal dysfunction, 13 (44.8%) had lung toxicity,
severe nephrotoxicity (Grades 2 and 3 renal dysfunction; 15 (51.7%) had liver toxicity, and 6 (20.6%) had sepsis.
Table 5). TBI was also not found to be associated with an Of the 40 patients who needed ventilator support, 10
increased risk of developing renal dysfunction compared (25%) of them had Grade 2 and 24 (60%) had Grade 3
to non-TBI regimens (28/36 patients, 77.7% with TBI vs. renal dysfunction. There was an 87.5% mortality among
33/52, 63.4% of patients treated with non-TBI regimens). the patients who required ventilator support. The fre-
quency of hypotension was higher in patients with severe
Associated complications with severe nephrotoxicity nephrotoxicity but the difference did not reach statistical
Grade 3 renal dysfunction was associated with a signifi- significance. There was no significant difference in am-
cantly increased risk of mortality (24/29 patients; 82.7%) photericin B therapy and aminoglycoside therapy be-
at the end of 6 months. The patients with Grade 3 renal tween the Grade 2 and 3 patients and the Grade 0 and
dysfunction died relatively early at an average of 47  1 patients.
20 days. The mortality rates of patients with Grade 0 Univariate analysis comparing patients with Grade 3
(3/7 patients; 42.8%), Grade 1 (8/20 patients; 40%), and renal dysfunction versus Grades 0 to 2 renal dysfunction
Grade 2 (16/32 patients; 50%) renal dysfunction was demonstrated no statistical differences in age, diagnosis,
significantly lower than mortality seen in Grade 3 (P  baseline serum albumin, serum bilirubin, hypotension,
role of aminoglycosides, or amphotericin B. However,0.01). The mortalities occurred at an average of 70  50
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significant differences were observed with the frequency shorter time from transplantation to death of 48  30
of sepsis (3.28% in Grades 0 to 2 vs. 21.74% in Grade 3 days compared with the 11 mortalities in patients with
renal dysfunction; P  0.05), hepatic VOD (9.8% in Grade 0 or 1 renal dysfunction (102  48 days, P 0.01).
Grades 0 to 2 vs. 31% in Grade 3 renal dysfunction; P  The average baseline serum creatinine concentration
0.01), and lung toxicity (16.9% in Grade 0 to 2 vs. 44.8% for the 40 mortalities associated with severe nephrotoxic-
in Grade 3 renal dysfunction; P 0.001). However, with ity (Grade 2 or Grade 3 renal impairment) was 0.79 
multivariate analysis, age, diagnosis, chemotherapy pro- 0.31 mg/dL, with an average doubling time of 14.1  5.5
tocols, baseline serum albumin, serum bilirubin, and sep- days. Analysis of the 21 surviving patients with similar
sis were not significantly correlated with the Grade 3 grades of renal dysfunction revealed a baseline serum
renal dysfunction. However, lung toxicity (P  0.01) creatinine concentration of 0.75  0.13 mg/dL with an
and hepatic VOD (P  0.05) were significantly associ- average doubling time of 17.3  5.9 days. There was no
ated with Grade 3 renal dysfunction in both univariate significant difference in serum creatinine levels in these
and multivariate analysis. groups, however the doubling time of serum creatinine
was significantly shorter in patients with severe nephro-
Cyclosporine A toxicity
toxicity who died (P  0.01). The 11 mortalities with
Seventy-four of the patients studied had serum levels either none or mild (Grade 1) renal dysfunction had a
of CsA measured throughout the first month after trans- baseline serum creatinine of 0.82  0.21 mg/dL.
plantation. The average CsA level (ng/mL) for patients The diagnosis-associated six-month mortality rates
in the four groups of renal dysfunction did not differ were as follows: AML, 78.26% (18 of 23); CML, 36.4%
significantly: Grade 0, 447  53 ng/mL (range 327 to (8 of 22); ALL, 70% (7 of 10); NHL, 53.3% (8 of 15);
528); Grade 1, 420  22 ng/mL (range 387 to 448); breast cancer, 57.14% (4 of 7); CMML, 100% (1 of 1);
Grade 2, 405  49 ng/mL (range 387 to 448); Grade 3, CLL, 33.3% (1 of 3); Hodgkin’s lymphoma, 50% (2 of
416 58 ng/mL (range 197.43 to 497.61). There was also 4); myelodysplastic syndrome, 100% (1 of 1); multiple
no significant difference in average CsA levels between myeloma, 50% (1 of 2). No diagnosis was found to be
survivors (421  49, range 217 to 542 ng/mL), and non-
correlated with mortality, although the statistical power
survivors (410  37, range 197 to 497 ng/mL; P  0.1).
is obviously limited.
The six-month mortality rates associated with the dif-Hepatotoxicity
ferent conditioning regimens were as follows: melphalanAll patients were monitored closely for signs of liver
TBI, 63.6% (21 of 33); busulfanmelphalan, 58.3% (14toxicity and the majority of patients did exhibit labora-
of 24); cyclophosphamide  busulfan, 50% (14 of 28);tory evidence of hepatotoxicity, in particular increased
cyclophosphamide TBI, 66.6% (2 of 3). There were nolevels of transaminases and/or and hyperbilirubinemia
differences in any of the different chemotherapy groups(both defined as increases in serum levels greater than 2
in terms of mortality. The mortality of patients who weretimes the normal). Overall, 82 patients (93%) developed
treated with regimens including cyclophosphamide wassome hepatotoxicity. Fifty-three patients (60%) had only
51.6% (16 of 31), while the mortality of patients whoelevated serum transaminases, 75 patients (85.2%) had
did not receive this drug was 61.4% (35 of 57). This dif-elevated serum bilirubin levels, and 46 patients (52.2%)
ference was not significant.showed elevations in both serum transaminases and bili-
rubin levels. Only 6 of the 88 patients (6.81%) did not
have any hepatic toxicity. Of the 46 patients with both DISCUSSION
transaminitis and hyperbilirubinemia, 15 had Grade 3
Allogeneic HCT is becoming an increasingly utilizedand 17 had Grade 2 renal dysfunction. Included among
procedure to treat a variety of hematological malignan-these are the 7 patients who developed severe hepatic
cies. The major indications for allogeneic HCT includeVOD, 6 of whom required hemodialysis and died.
hematological malignancies such as AML, ALL, CML,
Mortality marrow failure states such as aplastic anemia and genetic
disorders such as -thalassemia. From the standpoint ofThe overall mortality rate for the 88 allogeneic HCT
overcoming graft rejection and GVHD, ideally the donorwas 58% (51 of 88) at the end of six months. The mortal-
should be as genetically similar to the patient as possible,ity rates for the four grades of renal dysfunction are as
with a transfer between monozygous twins being theshown in Table 3. The mortality in patients with at least
best scenario. The next best choice is to use a humana doubling of their serum creatinine concentration was
lymphocyte antigen (HLA)-matched sibling; however,65.5% (40 of 61). The mortalities occurred at an average
only 30 to 40% of Americans have an HLA-identicalof 60  40 days after the transplantation. Of the 51 de-
relative [8]. The majority of patients are therefore leftceased patients, the 40 patients with either Grade 2 or
Grade 3 renal impairment demonstrated a significantly with two choices, a closely HLA-matched unrelated do-
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Table 7. Differences in the rates of renal dysfunction andnor or an HLA-mismatched relative. Studies have sug-
mortality in autologous versus allogeneic HCT
gested that the former provides a better outcome [9].
Autologousa Allogeneic P valueAllogeneic HCT involves administration of high dose
Number of patients 232 88of chemoradiotherapy to destroy the tumor cells and at
Grade 0 renal dysfunction 44% 8% 0.001the same time suppress the host’s immune system to
Grade 1 renal dysfunction 35% 23% 0.058
prevent graft rejection. In addition, post-transplant im- Grade 2 renal dysfunction 14% 36% 0.001
Grade 3 renal dysfunction 7% 33% 0.001munosuppression such as CsA and methotrexate are uti-
VOD 4% 16% 0.001lized to prevent GVHD. While this approach can be
Lung toxicity 13% 26% 0.001
successful because the donor cells provide hematopoietic Mortality 7% 58% 0.001
recovery, the non-hematopoietic toxicities are dose lim- a Details of the autologous data are in [5]
iting. Organ toxicities beyond the bone marrow are com-
mon and potentially life threatening.
In contrast to allogeneic HCT, autologous HCT in-
volves using patient’s own previously stored cells to re- what higher than in some reports in allogeneic HCT [4],
the 60% of doubling of serum creatinine was compar-establish hematopoietic cell function after the adminis-
tration of high-dose chemotherapy. Because there is no able to other studies [10]. Although the differences be-
tween the autologous and allogeneic are highly signifi-risk of GVHD and thus no requirement for using im-
munosuppressive agents, autologous HCT is safer than cant (Table 7), it should be noted that the autologous
HCT study included the cohort of patients from yearsallogeneic HCT and can be readily performed in patients
up to 70 years of age. A drawback of the autologous HCT 1991 to 1994 [5], while the current study includes patients
from years 1995 to 2000.is the lack of graft versus tumor effect and thus the risk
of relapse of original disease is greater than with allo- Cyclosporine A (CsA) has been used for almost 20
years in the prevention and treatment of GVHD, a com-grafting. Also, autografting is not feasible for patients
with tumor involvement of the bone marrow. mon occurrence after allogeneic HCT due to T-cell re-
sponses against the minor histocompatibility antigens.The present study examined the effect of allogeneic
transplantation on renal function. In our previous study While CsA has many advantages, including a lack of mye-
losuppression, its major drawback is associated renal tox-of 232 patients with breast cancer who received autolo-
gous HCT [5], only 21% of the patients were found to icity. The mechanism for this toxicity is thought to be
both related to enhanced Ca2 uptake by vascular smoothdevelop Grades 2 to 3 renal dysfunction. The overall mor-
tality for autologous transplantation was 6.89%, while muscle and contraction of mesangial cells [11]. Serum
CsA levels have been shown to correlate with renal toxic-the mortality rate in patients with Grades 2 to 3 renal
dysfunction was 18.4%. In contrast, the present results ity [12]. The addition of amphotericin B, frequently
needed for treatment of neutropenic fevers, in combina-demonstrated that allogeneic transplantations carry a
much higher mortality rate (58%) and that renal dysfunc- tion with CsA further increases the renal toxicity [13].
In this regard, the newer lipid-based amphotericins andtion is a very common occurrence. Of the 88 allogeneic
transplant patients in this study, 51 (58%) had a doubling echinocandins offer some promise to attenuate this com-
bined nephrotoxicity. In the present study, no correlationin serum creatinine concentration during the first month
of treatment. There are various reasons for this impor- was found between blood CsA levels and the incidence
of renal failure. However, although CsA levels did nottant difference. First, autologous transplants for breast
cancer are considered relatively low risk procedures com- correlate with nephrotoxicity in this study, CsA likely
has an etiologic role in renal dysfunction after allogeneicpared to autologous transplants for other malignancies.
Second, among our allogeneic HCT patients a relatively HCT or one of the several insults in insults against the
kidney during the treatment.high proportion of patients, approximately 50%, were re-
cipients of cord blood and unrelated donor transplants, Liver disease is also commonly viewed as a side effect
of HCT, and a particular concern is the development ofwhich are known to have a comparatively high mortality
as compared to transplants from matched sibling donors. hepatic VOD. Zager discussed the possible deleterious
effects of hepatic dysfunction on the kidneys, and sug-Third, the present study, unlike previous studies, evalu-
ated patients exclusively with allogeneic HCT transplants. gested that the decreased renal perfusion and resultant
pre-renal azotemia associated with liver damage has anThe aim of the present study was to examine the differ-
ences in the rates of renal dysfunction and mortality in important role in inducing renal failure [3]. We found
that greater than 75% of the allogeneic HCT patientsallogeneic versus autologous HCT (Table 7). These find-
ings clearly indicate that autologous and allogeneic HCT developed liver abnormalities within the first month of
treatment. Of the 14 patients with VOD, three hadshould be considered as substantially different entities
in terms of nephrotoxicity risks. While the overall inci- Grade 2 and nine had Grade 3 renal dysfunction. The
mortality rate for the 9 patients with VOD accompanieddence of renal dysfunction in the present study is some-
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with Grade 3 renal dysfunction was 100%. These findings opment of GVHD and its numerous serious sequelae.
The time course of renal failure here suggests that anysupport the notion that liver and renal toxicities are
potential therapeutic agent to prevent renal dysfunctionclosely linked.
will need to be started soon after the allogeneic HCTThe early time course of the renal dysfunction (occur-
and continued for two to three weeks to prevent renalring on average after the second week post-transplant)
dysfunction.may provide some support for a hemodynamic as well
as nephrotoxic insult. Amphotericin B is commonly used Reprint requests to Robert W. Schrier, M.D., Department of Medi-
in allogeneic transplants as it was in the present study. cine, University of Colorado Health Sciences Center, 4200 East 9th Ave-
nue, Campus Box B178, Denver, Colorado 80262, USA.It is usually initiated within the first few weeks of trans-
E-mail: Robert.Schrier@UCHSC.eduplant as either empiric therapy for prolonged neutro-
penic fevers or for treatment of documented fungal infec-
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